Loop Industries, Inc. (LOOP) Forms $16.70 Double Top; Continental Advisors Has Cut Its Myriad Genetics (MYGN) Holding

Loop Industries, Inc. (LOOP) formed double top with $17.54 target or 5.00% above today’s $16.70 share price. Loop Industries, Inc. (LOOP) has $547.88M valuation. The stock decreased 1.76% or $0.3 during the last trading session, reaching $16.7. About 15,562 shares traded or 29.13% up from the average. Loop Industries, Inc. (NASDAQ:LOOP) has 0.00% since January 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Continental Advisors Llc decreased Myriad Genetics Inc (MYGN) stake by 41.43% reported in 2017Q3 SEC filing. Continental Advisors Llc sold 24,900 shares as Myriad Genetics Inc (MYGN)’s stock rose 13.21%. The Continental Advisors Llc holds 35,200 shares with $1.27 million value, down from 60,100 last quarter. Myriad Genetics Inc now has $2.50 billion valuation. The stock increased 1.46% or $0.52 during the last trading session, reaching $36.05. About 670,506 shares traded. Myriad Genetics, Inc. (NASDAQ:MYGN) has declined 37.47% since January 15, 2017 and is downtrending. It has underperformed by 54.17% the S&P500.

Since September 1, 2017, it had 0 insider purchases, and 3 selling transactions for $1.36 million activity. On Friday, September 1 the insider HENDERSON JOHN T sold $909,040. On Monday, December 11 DREISMANN HEINRICH sold $201,000 worth of Myriad Genetics, Inc. (NASDAQ:MYGN) or 6,000 shares. GILBERT WALTER PHD sold $248,925 worth of Myriad Genetics, Inc. (NASDAQ:MYGN) on Thursday, December 14.

Continental Advisors Llc increased Powershares Qqq Trust (Put) (QQQ) stake by 2,700 shares to 138,000 valued at $20.07M in 2017Q3. It also upped Perrigo Co Plc (NYSE:PRGO) stake by 36,200 shares and now owns 56,200 shares. Opus Bk Irvine Calif (NASDAQ:OPB) was raised too.

Among 20 analysts covering Myriad Genetics (NASDAQ:MYGN), 4 have Buy rating, 4 Sell and 12 Hold. Therefore 20% are positive. Myriad Genetics had 50 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Market Perform” rating by Wells Fargo given on Tuesday, August 25. The stock of Myriad Genetics, Inc. (NASDAQ:MYGN) earned “Neutral” rating by PiperJaffray on Wednesday, August 10. The rating was maintained by Barclays Capital on Wednesday, August 9 with “Equal-Weight”. The rating was upgraded by Deutsche Bank on Friday, August 18 to “Hold”. The firm has “Underweight” rating given on Wednesday, August 10 by Morgan Stanley. The stock of Myriad Genetics, Inc. (NASDAQ:MYGN) earned “Hold” rating by Jefferies on Monday, June 12. The rating was upgraded by Ladenburg Thalmann to “Neutral” on Wednesday, February 8. The stock of Myriad Genetics, Inc. (NASDAQ:MYGN) has “Overweight” rating given on Tuesday, September 15 by Piper Jaffray. The stock has “Buy” rating by Deutsche Bank on Thursday, January 7. Barclays Capital downgraded the stock to “Equal-Weight” rating in Wednesday, August 10 report.

Analysts await Myriad Genetics, Inc. (NASDAQ:MYGN) to report earnings on February, 6. They expect $0.24 earnings per share, down 7.69% or $0.02 from last year’s $0.26 per share. MYGN’s profit will be $16.62 million for 37.55 P/E if the $0.24 EPS becomes a reality. After $0.26 actual earnings per share reported by Myriad Genetics, Inc. for the previous quarter, Wall Street now forecasts -7.69% negative EPS growth.